title: [Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment].
abstract: The early detection of macular toxicity linked to long-term antimalarial treatment requires regular ophthalmological screening based on patients'classification based on their results compared to successive controls. Patients are classified as "low risk" with screening every 18 months if all of the following criteria are met: age under 65 years, no associated renal, hepatic or retinal disease, treatment for less than 5 years, dose less than or equal to 6,5mg/kg/d for hydroxychloroquine and 3mg/kg/d for chloroquine (for a lean patient's weight); "at risk, without fundus findings" with screening every 12 months if one of the following criteria is met: age over 65 years (at the start of or during treatment), antimalarial treatment for more than 5 years, daily dose higher than recommended, presence of renal and/or hepatic disease; "at risk, with fundus findings" with screening every 6 months if a retinal dysfunction has been detected and even if treatment is established or followed. Screening consists of an in-depth clinical examination and at least two complementary tests of macular function: color vision (desaturated-Panel-D15 test) and/or static macular perimetry (central 10 degrees) and/or macular electroretinography (pattern ERG/multifocal ERG). If any changes or anomalies are found between two successive check-ups, the state of the retina can be assessed by angiography and global retinal function by full-field-ERG and electro-oculogram (EOG). The progression from one check-up to the next decides whether a course of treatment will be followed.
authors.affiliation: Service d'Exploration Fonctionnelle de la Vision (Biophysique), Hôpital Lariboisière, Paris. rigaud@ext.jussieu.fr
authors.forename: F
authors.initials: F
authors.lastname: Rigaudière
authors.forename: I
authors.initials: I
authors.lastname: Ingster-Moati
authors.forename: J-C
authors.initials: JC
authors.lastname: Hache
authors.forename: J
authors.initials: J
authors.lastname: Leid
authors.forename: R
authors.initials: R
authors.lastname: Verdet
authors.forename: P
authors.initials: P
authors.lastname: Haymann
authors.forename: M-H
authors.initials: MH
authors.lastname: Rigolet
authors.forename: X
authors.initials: X
authors.lastname: Zanlonghi
authors.forename: S
authors.initials: S
authors.lastname: Defoort
authors.forename: J-F
authors.initials: JF
authors.lastname: Le Gargasson
mesh_terms: D000962:Antimalarials / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D008266:Macula Lutea; D011358:Product Surveillance, Postmarketing; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D018570:Risk Assessment; D013997:Time Factors
chemical_list: D000962:Antimalarials